At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
GLWL-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
In Brief
A Phase 2 clinical trial evaluating GLWL-01 and Placebo for Prader-Willi Syndrome. Completed, enrolled 19 participants across 7 sites in 2 countries.
Detailed Summary
The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrader-Willi Syndrome
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartFeb 2018
Primary CompletionJun 2019
TodayJul 2026
First PostedSep 7, 2017
Enrollment StartFeb 20, 2018
Primary CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.8 years ago
Interventions
GLWL-01drug
Oral administration of 3 capsules, twice a day
Placebodrug
Oral administration of 3 capsules, twice a day